Key facts
- It has raised $4.9M; the latest was Later Stage VC ($2.0M) in Oct 2024.
- Notable investors include Nippon Venture Capital, UntroD, NOW (Japan), Beyondge, Bio Engineering Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AOI Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for AOI Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AOI Biosciences
Developer of a genome detection and analysis technology designed to develop diagnostic drugs using enhancers or m-ribonucleic acid. The company's technology helps analyze data on infectious diseases and healthcare with external companies and academia and develop artificial intelligence, enabling pharmaceutical companies to diagnose diseases of ribonucleic acid transcript expression fluctuations from the seed search stage.
- Sector
- Healthcare
- HQ
- Suita, Japan
- Founded
- 2019
- Website
- aoibio.com/
- Ownership
- Privately Held (backing)
AOI Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AOI Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AOI Biosciences in its N-PORT filings yet. We sweep new filings monthly.